Study of the Costs of Treating End-Stage Renal Failure in Dialysis Patients at the Aristide Le Dantec Hospital (Senegal) in 2019

Chronic kidney disease (CKD) is a major global public health issue. Its treatment is financially and socially costly, particularly in the terminal stage. The objective of this study was to evaluate the costs of dialysis in patients with end-stage renal disease undergoing dialysis at the Aristide Le Dantec Hospital in Dakar. We conducted an analytical cross-sectional study with an economic focus from January 2, 2019, to June 21, 2021. A documentary review of medical records was carried out, coupled with the administration of a questionnaire to each patient meeting the inclusion criteria. Data relating to sociodemographic characteristics, epidemiology, and economics were evaluated. The database was analyzed using Epi Info version 7 software. Among the 89 patients included, 58.43% were already in the terminal stage at the time of CKD diagnosis. The initial nephropathy was dominated by vascular nephropathy, followed by CGN and CIDN, with 45.74%, 30.85%, and 10.63%, respectively. The average annual direct costs for PD patients were 1148 057 ± (792 576) CFA francs; for hemodialysis patients, these costs amounted to 1 560 417 ± (1 224 868) CFA francs. The total cost of care for all dialysis patients amounted to 1 481 922 405 CFA francs, of which 698 563 200 CFA francs (47.14%) were covered by the state and 783 359 205 CFA francs (52.86%) by the patients. The average annual cost of biological tests, travel, and special diets was statistically higher for HD patients than for other patients receiving PD (P value < 0.05). Prevention of this condition is essential in its management in order to limit or avoid its negative effects. Kidney transplantation remains a very promising alternative.